A phase 1 trial co-led by Michael Bishop, MD, at the UChicago MedIcine, found that investigational BCMA-targeted CAR-T therapy anito-cel produced deep, durable responses in relapsed/refractory multiple myeloma. #CAR-TTherapy #MultipleMyeloma #BCMATargeted
https://ow.ly/agH950ZRalu